PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ)

$0.0071 0 (0%)

watchlist-icon
search-icon
Profile Icon

Most Recent Average Sentiment Analysis Score (0 to 100): 84

negative-sentiment
Negative [0, 35)
neutral-sentiment
Neutral [35, 65]
positive-sentiment
Positive (65, 100]
Visualize Sentiment Trendline

Analysed PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ) News Sources

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

01-04-2026

yahoo.com

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

04-11-2025

yahoo.com

Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

16-09-2025

yahoo.com

Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

08-09-2025

yahoo.com

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

29-08-2025

yahoo.com

Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

28-08-2025

yahoo.com

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

31-07-2025

yahoo.com

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

11-06-2025

yahoo.com

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

02-06-2025

yahoo.com

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases

20-05-2025

yahoo.com

KTTAW stock
KTTAW stock price
KTTAW stock price today
KTTAW stock prediction
KTTAW earnings date
KTTAW news
KTTAW price
KTTAW share
KTTAW share price
KTTAW shares
KTTAW ceo
KTTAW premarket
$KTTAW
KTTAW ticker
KTTAW after hours
KTTAW stock
KTTAW stock price
KTTAW stock price today
KTTAW stock prediction
KTTAW earnings date
KTTAW news
KTTAW price
KTTAW share
KTTAW share price
KTTAW shares
KTTAW ceo
KTTAW premarket
$KTTAW
KTTAW ticker
KTTAW after hours

PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ) Sentiment Trend

View FAQ

PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ) FAQs

toggle

What is the current price of PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ)?

The current price of PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ) is $0.0071.


toggle

PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ) absolute price change since previous trading day?

The absolute price change of PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ) since the previous trading day is $0.


toggle

PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ) percentage price change since previous trading day?

The percentage price change of PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ) since the previous trading day is 0%.


toggle

What is the most recent average sentiment score for PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ)?

The most recent average sentiment score for PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ) is 84 out of 100.


toggle

What is the most recent average sentiment for PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ)?

The most recent sentiment for PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ) is .


SEC-8K** Filing Available For PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ)

** material developments that could impact a company's financial condition or stock price.

Author: MattELab

X Icon

GitHub Icon

MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.